Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)

NCT02104583 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02104583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02104583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2014
Completion date
October 31, 2016
Enrollment
313 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

ventricular arrhythmia